Trial Profile
A Phase 2 Study of Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms PULSAR
- 19 Oct 2021 Status changed from recruiting to discontinued.
- 21 Jan 2017 Interim results (n=30) assessing safety and efficacy presented at the 2017 Gastrointestinal Cancers Symposium.
- 15 Feb 2016 Planned End Date changed from 1 Apr 2017 to 1 Jul 2017 as reported by ClinicalTrials.gov record.